INO (Inovio Pharmaceuticals) שווי פירמה כולל

Inovio Pharmaceuticals (INO) is concluding a prolonged research cycle as it prepares to launch its debut DNA-based drug for the treatment of respiratory papillomatosis. The company leads the development of genetic medicines while awaiting approval for INO-3107 and confirmation of its platforms' efficacy. This market valuation chart with a value of 63.36 complements data on CELLECTRA systems, which automate the contactless delivery of vaccines into tissues to eliminate personnel errors.

Enterprise Value (EV) combines market capitalization and net debt, reflecting the actual price of a full business acquisition regardless of the financing structure. By analyzing the total enterprise value chart for Inovio Pharmaceuticals (INO), an investor assesses the extent to which the market price aligns with the value of the unique CELLECTRA electroporation technology, separating speculative volatility from the fundamental value of innovative developments in DNA medicine.